[go: up one dir, main page]

AR061357A1 - COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA - Google Patents

COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA

Info

Publication number
AR061357A1
AR061357A1 ARP070102582A ARP070102582A AR061357A1 AR 061357 A1 AR061357 A1 AR 061357A1 AR P070102582 A ARP070102582 A AR P070102582A AR P070102582 A ARP070102582 A AR P070102582A AR 061357 A1 AR061357 A1 AR 061357A1
Authority
AR
Argentina
Prior art keywords
bifeprunox
dopa
preparations including
combination preparations
treatment
Prior art date
Application number
ARP070102582A
Other languages
Spanish (es)
Inventor
Martinus Th M Tulp
Andrew C Mccreary
Scharrenburg Gustaaf J M Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR061357A1 publication Critical patent/AR061357A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere al uso de una preparacion combinada de bifeprunox o su N-oxido o sales farmacéuticamente aceptables de estos compuestos: y L-DOPA, para el uso simultáneo, separado o secuencial en el tratamiento de trastornos que requieren la recuperacion de la funcion dopaminérgica, en particular la enfermedad de Parkinson y el síndrome de las piernas inquietas. Composicion farmacéutica, método de tratamiento.This refers to the use of a combined preparation of bifeprunox or its N-oxide or pharmaceutically acceptable salts of these compounds: and L-DOPA, for simultaneous, separate or sequential use in the treatment of disorders that require recovery of function. dopaminergic, particularly Parkinson's disease and restless legs syndrome. Pharmaceutical composition, treatment method.

ARP070102582A 2006-06-16 2007-06-13 COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA AR061357A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06115587 2006-06-16

Publications (1)

Publication Number Publication Date
AR061357A1 true AR061357A1 (en) 2008-08-20

Family

ID=37156018

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102582A AR061357A1 (en) 2006-06-16 2007-06-13 COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA

Country Status (7)

Country Link
CN (1) CN101478990A (en)
AR (1) AR061357A1 (en)
BR (1) BRPI0713691A2 (en)
MX (1) MX2008016226A (en)
SA (1) SA07280316B1 (en)
TW (1) TW200815031A (en)
UA (1) UA94465C2 (en)

Also Published As

Publication number Publication date
BRPI0713691A2 (en) 2012-10-30
TW200815031A (en) 2008-04-01
SA07280316B1 (en) 2010-10-19
UA94465C2 (en) 2011-05-10
CN101478990A (en) 2009-07-08
MX2008016226A (en) 2009-01-19

Similar Documents

Publication Publication Date Title
CL2007001918A1 (en) SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
DOP2011000373A (en) DERIVATIVES OF 1H-IMIDAZO- [4,5-C] -QUINOLINONA
CL2007003609A1 (en) COMPOUNDS DERIVED FROM REPLACED DIHYDROPIRIDINES; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; PROCESS TO PRODUCE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF A DISEASE IMPROVED WITH INHIBITION
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
BRPI0607762B8 (en) glp-1 analogues, pharmaceutical composition containing them and use of a compound
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
ECSP088297A (en) 7- [2- [4- (6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL) -1-PIPERAZINIL] ETIL] -2- (1-PROPINYL) -7H-PIRAZOL- [4, 3-e] - [1,2,4] -TRIAZOL- [1,5-C] -PIRIMIDIN-5-AMINA
UY32691A (en) 1H-IMIDAZO- [4,5-C] -QUINOLINONA COMPOUNDS
BRPI0908124A2 (en) Compound, glucokinase activator, pharmaceutical composition, use of a pharmaceutically acceptable salt or compound thereof, and methods of activating glucokinase, and to treat and / or prevent a disease.
AR063538A1 (en) TREATMENT OF PARKINSON'S DISEASE
BRPI0814666A2 (en) pharmaceutical composition for oral administration, use of a formulation. process for preparing a solid dosage form, and, solid dosage form
BRPI0509655A (en) use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and new 9h-purine-2,6-diamine derivatives
AR070025A1 (en) USE OF DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF COCLEAR TINNITUS AND PHARMACEUTICAL COMPOSITION
CL2007002574A1 (en) ORAL PHARMACEUTICAL COMPOSITION INCLUDING LEVODOPA IN A UNIT DOSE OF AROUND 100 TO AROUND 500 MG AND AN ADEQUATE EXCIPIENT; AND ITS USE TO TREAT PARKINSON.
AR057946A1 (en) FORMULATION OF SUSTAINED RELEASE ZONISAMIDE
CL2009001267A1 (en) Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.
EA200970022A1 (en) COMBINED PREPARATIONS CONTAINING BIFEPRUNOX AND L-DOSP
SV2010003773A (en) 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME
UY30126A1 (en) A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS
PE20030277A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING 2- [5- (4-FLUOROPHENIL) -3-PYRIDYLMETHYLAMINOMETHYL] -CHROMANE AND L-DOPA
BRPI0607413A2 (en) pharmaceutical composition comprising indolylmaleimide derivatives
AR074246A1 (en) DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF SOIL DISORDERS
AR061357A1 (en) COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA
CL2008002465A1 (en) Topical anhydrous pharmaceutical composition, comprising niacin derivatives and an acceptable carrier, its application allows improved sexual well-being.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal